INTRODUCTION
We estimated vaccine effectiveness (VE) of JN.1 COVID-19 vaccination against SARS-CoV-2 infection by (sub)variant between 23 September 2024 and 23 February 2025.
METHODS
JN.1 vaccine-eligible participants of an ongoing prospective cohort study (VAccine Study COvid-19; VASCO) were included: individuals ag...
Anne J. Huiberts, D. Eggink, B. de Gier et al.· Vaccine· 0 citations
INTRODUCTION
With still high circulation of pertussis and risk for severe disease in young children, insight into vaccine effectiveness (VE) of infant pertussis vaccination is important. In the Netherlands, NIP period 1 corresponds to the period during which the DT3aP-IPV-Hib-HBV vaccine and the 3 + 1 dose schedule wer...
D. van Meijeren, A. V. van Roon, B. de Gier et al.· Vaccine· 0 citations
A lower likelihood of subsequent COVID-19 booster uptake after experiencing systemic AE, particularly when severe or prolonged, or when experiencing a severe local AE is found, underscore the need to address experienced AE in communication strategies, as this may influence the success of vaccination campaigns.
Anne J. Huiberts, Maud M J Smits, C. Hoeve et al.· Vaccine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.